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Presentation with severe acute kidney injury due to cast nephropathy (CN) is a medical emergency in 
multiple myeloma (MM) with high risk of dialysis-dependent renal failure and death. Accrual of patients 
with CN into interventional studies is difficult, while phase III trials exclude patients with severe renal 
insufficiency. Real-world data are warranted. We assessed 2252 patients from the population-based 
Danish Multiple Myeloma Registry (DMMR), diagnosed 2013-2017. We identified 204 patients with 
clinically suspected CN, defined as serum creatinine concentration >177 µmol/L and serum free light 
chain (sFLC) concentration >1000 mg/L at the time of diagnosis. The median age was 72 years. Thirty-
one percent of patients presented with dialysis-dependent renal failure. Kidney biopsies were 
performed in 19% of patients and showed CN in 74% of cases. Despite prompt initiation of bortezomib-
based therapy in 94% of patients, 33% of patients died in the first year after diagnosis.  
Compared with the rest of the patients in the DMMR with symptomatic MM, patients with clinically 
suspected CN had worse overall survival (OS) irrespective of transplant eligibility. Achievement of renal 
recovery was associated with deep reductions of involved sFLC. Achievement of very good partial 
response or better in the first line of therapy and/or deep reduction of involved sFLC at three months 
after initiation of therapy were associated with superior OS. In conclusion, MM patients presenting with 
clinically suspected CN have an alarmingly high one-year mortality when treated with current standards 
of care. Early and deep hematologic response is crucial for survival. 
 
INTRODUCTION 
Renal failure, defined by serum creatinine higher than 177 µmol/L occurs in approximately 20-30% of 
patients with multiple myeloma (MM) at the time of diagnosis.1–4 Severe renal impairment requiring 
hemodialysis occurs in 3-9% of all patients with newly diagnosed MM, and unless renal function is 
recovered, it leads to considerable mortality during the first months after diagnosis. 1,2,5–10 Myeloma cast 
nephropathy (CN) is the most common form of monoclonal immunoglobulin-mediated kidney 
disease.11,12 It results from the interaction of excessive amounts of monoclonal light chains with Tamm-
Horsfall proteins in the distal tubule leading to precipitation of light chains and obstruction of the lumen 
of the distal nephron.13,14 Cast nephropathy causes around 70% of the cases of dialysis-dependent renal 
failure in MM and is a medical emergency requiring prompt intervention to rescue the kidneys from 
irreversible damage.12,14–19   
The serum free light chain (sFLC) assay is useful for identifying and monitoring patients with light chain 
myeloma and is an important tool during the initial screening of patients with unexplained acute renal 
failure.14,20–22 In such cases, the finding of a high sFLC concentration with an abnormal sFLC ratio raises 
the clinical suspicion of CN.14 Although the histopathologic diagnosis of CN is established by a 
percutaneous kidney biopsy, in routine clinical practice, the diagnostic yield of this procedure is often 
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outweighed by the urgent need of anti-myeloma treatment and the risk of procedure-related 
complications.14,23,24  
Accrual of patients with clinically suspected CN into clinical trials is challenging. This was demonstrated 
by two randomized clinical trials with the objective of assessing renal recovery and survival of newly 
diagnosed patients with MM and CN treated with or without high cut-off hemodialysis.25,26 Both trials 
required dialysis-dependent renal failure and histopathologic diagnosis of CN for inclusion. The MYRE 
study was conducted between 2011 and 2016 at 48 French centers and recruited 98 patients.25 The 
EULITE trial was conducted between 2008 and 2013 in 14 British and 2 German centers and recruited 90 
patients.26 While interventional studies struggle to include patients with CN, patients with severe renal 
failure are excluded from most phase III clinical trials.27 Real-world data in patients with clinically 
suspected CN are warranted. 
We conducted a retrospective, national, patient chart review in patients with newly diagnosed MM and 
clinically suspected CN. The aims of our study were to assess baseline characteristics, biopsy results, 
anti-myeloma treatment, renal recovery and overall survival in this patient group.  
 
METHODS 
We used five inclusion criteria to define the study population: (1) Patients had to be registered in the 
Danish Multiple Myeloma Registry (DMMR) with (2) newly diagnosed MM according to the International 
Myeloma Working Group (IMWG) criteria28 between (3)  1st of January 2013 and 31st of December 2017 
with (4) a serum creatinine concentration higher than 177 µmol/L and (5) an involved sFLC 
concentration higher than 1000 mg/L at the time of diagnosis (Figure 1 and Supplementary Figure 1A). 
The sFLC cutoff of 1000 mg/L was chosen based on kernel density analysis of the percentage of renal 
failure in relation to involved sFLC concentrations in patients from the DMMR diagnosed 2013-2017 
(Supplementary Figure 1B). The DMMR is a national registry that collects baseline and treatment-related 
data from myeloma patients diagnosed since the 1st of January 2005. The coverage of the population is 
close to 100%.29–36 Serum free light chain measurements have been routinely reported to this registry 
since 1st of January 2013. After identification of patients, investigators from ten Danish centers reviewed 
patient charts and retrospectively registered predefined data in a designated Research Electronic Data 
Capture (REDCap) database between 1st of October 2018 and 1st of September 2019. All biopsy reports 
were reviewed by a nephropathologist for the purposes of this study. Lines of therapy were registered in 
the first 12 months after MM diagnosis. A line of therapy was defined according to the IMWG guidelines 
for the determination of the number of prior lines of therapy in MM.37 The best response to a given line 
of therapy was defined according to the IMWG uniform response criteria for MM.38 Time to next 
treatment (TNT) was defined as the length of time between the date of initiation of a line of therapy and 
the subsequent line of therapy. Pre-myeloma kidney function was defined based on the latest serum 
estimated glomerular filtration rate (eGFR) assessment prior to myeloma diagnosis. Grades of Chronic 
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Kidney Disease (CKD) were defined according to the Kidney Disease: Improving Global Outcomes 
(KDIGO) CKD Work Group 2012 Clinical Practice Guidelines; grades 1, 2, 3a, 3b, 4 and 5 were defined by 
eGFR values of ≥90, 60-89, 45-59, 30-44, 15-29 and <15 ml/min/1.73 m2, respectively.39,40 Acute kidney 
injury (AKI) stage at diagnosis was classified according to the KDIGO 2012 Clinical Practice Guideline for 
acute kidney injury; stages 1, 2 and 3 were defined as serum creatinine 1.5-1.9 times baseline or ≥25.5 
µmol/L increase, 2.0-2.9 times baseline, and 3.0 times baseline or increase in serum creatinine to ≥353.6 
µmol/L or initiation of renal replacement therapy, respectively.41 Kidney function and sFLC 
concentrations were assessed at the following time points: the date of first sFLC measurement, the end 
of the first cycle of anti-myeloma therapy, three months after initiation of therapy, six months after 
initiation of therapy and 12 months after initiation of therapy.  Renal response was assessed according 
to the IMWG criteria for the definition of renal response to anti-myeloma therapy.42 Renal recovery at 
the predefined time points was assessed according to the following simplified criteria: In patients with 
dialysis-dependent renal failure at diagnosis, renal recovery was defined as independence from dialysis. 
In patients without dialysis-dependent renal failure at diagnosis, renal recovery was defined as an 
improvement of at least one CKD grade: a rise in eGFR from <15 to ≥15, from 15-29 to ≥ 30, from 45-59 
to ≥ 60 or from 60-89 to ≥ 90 ml/min/1.73 m2. Overall survival (OS) was defined as the length of time 
between the date of diagnosis and the date of death or last contact. Overall survival data were acquired 




Continuous variables were described with median, range, interquartile range (IQR) and confidence 
interval (CI). Categorical variables were summarized using the number of observations and percentages 
as appropriate. Overall survival was estimated and visualized using the Kaplan-Meier method, and log-
rang tests were used to assess difference between survival curves. Associations with OS were assessed 
by Cox proportional hazards regression models, with estimates reported as Hazard Ratios. Statistical 
analysis was performed with the statistical software R v. 3.6.1 and the add-on packages ‘tidyverse’, 





In the study period, 2252 patients were registered in the DMMR. Diagnostic serum creatinine 
concentrations were available in 2249 patients. In addition to serum creatinine, diagnostic sFLC kappa 
and lambda concentrations were available in 2136 patients. Of these, 297 (14%) patients had a serum 
creatinine concentration higher than 177 µmol/L and 627 (29%) patients had an involved sFLC 
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concentration higher than 1000 mg/L. Two hundred and nine patients had both a serum creatinine 
concentration higher than 177 µmol/L and an involved sFLC concentration higher than 1000 mg/L and 
were included in the study. Medical records in 5 patients were not accessible. The study population thus 
consisted of 204 patients. The flow-chart for inclusion and identification of the study population are 
presented in Figure 1 and Supplementary Figure 1, respectively. Two patients had previously been 
diagnosed with monoclonal gammopathy of unknown significance (MGUS). Five patients did not receive 
treatment for MM. Of these, one patient had advanced renal cell carcinoma, one patient had prostate 
cancer, one patient had pre-existing dialysis-dependent hypertensive nephropathy and two patients 
chose not to receive treatment for MM due to advanced age. One hundred and ninety-nine patients 
received therapy. The median age at diagnosis was 72 (IQR: 65; 79) years. One hundred and thirty-six 
(67%) patients were men. The median serum creatinine and involved sFLC concentrations at diagnosis 
were 340 (IQR: 243; 530) µmol/L and 5677 (IQR: 2495; 11918) mg/L, respectively. Baseline 
characteristics are presented in Table 1. Pre-myeloma serum creatinine concentrations were available in 
169 (83%) patients and 165 (81%) patients had a pre-myeloma eGFR registered. The median pre-
myeloma serum creatinine concentration and eGFR were 89 (IQR: 77; 115) µmol/L and 66 (IQR: 47; 80) 
ml/min/1.73 m2, respectively. Nineteen (11%) patients had a pre-myeloma serum creatinine 
concentration higher than 177 µmol/L. Based on pre-myeloma eGFR, there were 23 (14%) patients with 
grade 1, 80 (49%) with grade 2, 27 (16%) with grade 3a, 15 (9%) with grade 3b, 16 (10%) with grade 4 
and five (2%) with grade 5 CKD. Acute kidney injury stage at diagnosis was assessable in 171 patients. Of 
these, 17 (10%) had AKI stage 1, 32 (19%) had AKI stage 2 and 122 (71%) had AKI stage 3. 
 
Kidney biopsies 
A kidney biopsy was carried out in 38 (19%) patients. In 25 (66%) of these patients, the kidney biopsy 
was performed prior to the diagnosis of MM. The median time from kidney biopsy to MM diagnosis was 
4 (IQR: 3; 8) days. In 13 (34%) patients, the kidney biopsy was done after the diagnosis of MM. The 
median time from MM diagnosis to kidney biopsy was 5 (IQR: 2; 7) days. The histopathologic diagnosis 
based on the kidney biopsy was CN in 28 (74%) cases. Besides CN, additional diagnoses were reported in 
12 patients. These diagnoses were acute tubular necrosis (n=3), acute interstitial nephritis (n=2), 
pyelonephritis (n=2), interstitial fibrosis (n=2), amyloidosis (n=1), hypertensive blood vessel changes 
(n=1), chronic interstitial nephritis (n=1), mesangioproliferative glomerulonephritis (n=1) and unspecific 
chronic changes (n=1). In the 10 biopsied patients who did not have CN, the following diagnoses were 
reported: renal cell carcinoma (n=2), amyloidosis (n=1), acute tubulointerstitial nephritis (n=1), chronic 
inflammation with fibrosis (n=1), unspecific changes (n=1), normal tissue (n=1), and unsuitable biopsy 
(n=3). Baseline clinical characteristics in biopsied patients with and without CN were similar 
(Supplementary Table 1). 
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Time from first serum free light chain measurement to initiation of therapy 
The first line of anti-myeloma therapy was initiated prior to the first sFLC measurement in three patients 
(day -3: two patients, day -1: one patient). The median time from the first sFLC measurement to 
initiation of anti-myeloma therapy was five (IQR: 2; 10) days (Supplementary Figure 2). The time from 
first sFLC measurement to initiation of therapy in the two patients with previously diagnosed MGUS 
were 1163 and 1432 days, respectively. 
 
Lines of therapy 
Within the first 12 months from diagnosis, 199 patients received one, 44 patients received two, 15 
patients received three, four patients received four, two patients received five and one patient received 
six lines of therapy. High-dose melphalan with autologous hematopoietic stem cell transplantation 
(HDT-ASCT) was carried out in 51 (25%) patients and was part of the first, second and third line of 
therapy in 45, four and two patients, respectively. The most frequently used drugs (other than steroids) 
were bortezomib (n=220), cyclophosphamide (n=100), melphalan (n=38), thalidomide (n=34) and 
lenalidomide (n=31). The most frequently used first-line regimens were bortezomib-dexamethasone 
(VD; n=70), cyclophosphamide-bortezomib-dexamethasone (CVD; n=57), bortezomib-melphalan-
prednisolone (VMP; n=16), bortezomib-thalidomide-dexamethasone (VTD; n=12) and bortezomib-
lenalidomide-dexamethasone (VRD; n=5). Bortezomib was administered as part of the first-line regimen 
in 188 (94%) patients. The most frequently used second line regimens were CVD (n=8), VMP (n=7), 
lenalidomide-dexamethasone (RD; n=5), thalidomide-cyclophosphamide-dexamethasone (CTD; n=4), 
daratumumab-lenalidomide-dexamethasone (DRD; n=3) and VTD (n=3). Hematologic response to the 
first and second lines of therapy is shown in Supplementary Figure 3. The reduction of involved sFLC 
concentration at the end of the first cycle of therapy, at three months, six months and twelve months 
after initiation of therapy is shown in Supplementary Figure 4. A cause of discontinuation was registered 
in 88% of the administered lines of therapy. The cause of discontinuation was fixed duration regimen in 
58 (25%), toxicity in 35 (15%), death in 34 (15%), plateau phase in 34 (15%), progressive disease in 31 
(13%), insufficient response in 12 (5%), poor performance status in 11 (5%), patient’s choice in 7 (3%), 
and “other” in 10 (4%) of cases. The causes of discontinuation of the first and second lines of therapy 
are shown in Supplementary Figure 5. The median TNT between the first and second line of therapy was 
46 (24; 101) days. 
 
Dialysis dependency and renal recovery 
Renal function was available in 188 patients at the end of the first cycle of therapy, 169 patients at three 
months, 157 patients at six months and 134 patients at 12 months after initiation of therapy. At these 
time points, 24%, 17%, 15% and 13% of patients had dialysis-dependent renal failure, respectively 
(Supplementary Figure 6A). Renal response according to the IMWG criteria is shown in Supplementary 
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Figure 6B. Renal recovery according to the simplified criteria defined in this study was achieved in 45% 
of patients at the end of the first cycle of therapy, in 66% of patients three months, in 72% of patients 
six months, and in 73% of patients 12 months after initiation of therapy (Supplementary Figure 6C). 
Achievement of renal recovery was associated with deeper reductions of involved sFLC at all time points 
(p=0.009 at the end of the first cycle of therapy, p=0.001 at three months, and p=0.002 at six months 
after initiation of therapy; Figure 2).  
 
Overall survival 
The median OS in the study population was 3.7 (95% CI: 2.6; 4.7) years (Supplementary Figure 7A). One-
year mortality was 33%. Of the 204 patients with accessible records, 190 (93%), 170 (83%), 158 (77%) 
and 136 (67%) patients were alive after the first cycle of therapy, at three months, six months and 12 
months after initiation of therapy, respectively. There were 1927 patients in the DMMR who did not 
fulfil the inclusion criteria for this study. The median OS of these patients was 6.1 (95% CI: 5.2; not 
reached) years. One-year mortality was 13%. Of the 1927 patients, 1393 had symptomatic MM. 
Compared with the rest of the patients in the DMMR with symptomatic MM, patients with clinically 
suspected CN had worse OS irrespective of HDT-ASCT-eligibility (p<0.001; Supplementary Figure 7B). 
One-year mortality was higher in both HDT-ASCT-eligible (6% vs. 2%) and HDT-ASCT-ineligible (43% vs. 
20%) patients.  
 
Factors associated with overall survival: 
The following baseline variables were associated with OS: age (HR: 1.78; p<0.001), performance status 2 
(HR: 2.19; p=0.006), performance status 3 (HR: 6.20; p<0.001), performance status 4 (HR: 6.80; p<0.001), 
serum albumin (HR: 0.95; p<0.001), beta-2-microglobulin (HR: 1.03; p=0.006), and LDH (HR: 1.00; 
p=0.022). High-dose melphalan with autologous hematopoietic stem cell transplantation performed in 
any line of therapy was associated with longer OS (HR 0.26; p<0.001). There was no difference in OS of 
HDT-ASCT-eligible nor HDT-ASCT-ineligible patients based on the administered first-line regimens 
(Supplementary Figure 8). In multivariate analysis adjusted for the effects of age, performance status, 
creatinine, albumin, LDH and HDT-ASCT, very good partial response or better in the first line of therapy 
(HR 0.46; p=0.002) and involved sFLC reduction to 10% or lower of baseline at three months after 
initiation of therapy (HR: 0.56; p=0.039) were independently associated with longer OS (Figure 3). 
 
DISCUSSION 
Our large real-world study provides nationwide data on the characteristics, treatment, renal recovery 
and OS of patients with newly diagnosed MM and clinically suspected CN, defined as serum creatinine 
higher than 177 µmol/L and involved sFLC higher than 1000 mg/L. This disease presentation was found 
in 10% of all MM patients. Despite the prompt initiation of effective bortezomib-based therapy in 94% 
This article is protected by copyright. All rights reserved.
 
 
of patients, one third of the patient group died in the first year after diagnosis; a mortality higher than in 
the rest of the patients registered in the DMMR who were diagnosed in the same period. One-year 
mortality was especially high in HDT-ASCT-ineligible patients. Patients who survived the crucial first year 
after diagnosis had comparable survival to the rest of the patients registered in the DMMR. Very good 
partial response or better in the first line of therapy and deep reduction of involved sFLC at three 
months resulted in superior OS.  
A strength of our study is the description of a group of patients who are underrepresented in clinical 
trials. Besides the inclusion criteria, the study population was unselected and population-based. All 
treatment decisions were results of real-world clinical scenarios. As expected, we observed higher one-
year mortality than reported in the MYRE and EULITE trials, even though these trials were conducted in 
more sick populations, having only included patients with dialysis-dependent real failure at the time of 
diagnosis.25,26 
A limitation of this study is the lack of systematic histological verification of CN. When performed, 
kidney biopsies showed CN in 74% of cases, similarly to the findings of previous biopsy studies in 
MM.17,18 A kidney biopsy is the only diagnostic method of CN; no threshold sFLC concentration or 
biomarker is specific for this mechanism of acute kidney injury. It is though generally assumed that CN 
does not develop in patients with an involved sFLC concentration lower than 500 mg/L.14 Our data, 
based on 2136 patients from the DMMR supported the use of a sFLC cutoff of 1000 mg/L for renal 
failure (Supplementary Figure 1). It is our opinion, that the sFLC assay, despite being unspecific for CN, 
together with the initial diagnostic work-up, provides sufficient clinical information to initiate acute 
treatment in most patients. We expect that CN remains a clinically suspected, rather than a 
histologically verified diagnosis in the future.  
The standard frontline treatment in our patient group consisted of CVD induction followed by HDT-ASCT 
in transplant-eligible patients, and VD in transplant-ineligible patients. Daratumumab is a monoclonal 
antibody that can be safely administered in patients with renal failure.48,49 There were only seven 
patients in our cohort that were treated with daratumumab, which had been reimbursed in Denmark 
since September 2016. At the time of writing of this manuscript, daratumumab has not yet been granted 
reimbursement for the frontline treatment of patients with MM in Denmark. However, it is expected, 
that daratumumab soon will be an available first-line option in MM patients presenting with clinically 
suspected CN, improving patient outcomes.  
In conclusion, MM patients presenting with clinically suspected CN, especially transplant-ineligible 
patients, have an alarmingly high one-year mortality when treated with current standards of care. Early 
and deep hematologic response and reduction of toxic free light chains are crucial for survival. The 
expected inclusion of daratumumab in future first-line regimens will likely improve outcomes in this 
group of MM patients. 
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Figure 1  
Flow-chart of the study population 
 
In the study period (2013-2017), 2252 patients were registered in the Danish Multiple Myeloma 
Registry. Diagnostic serum creatinine concentrations were available in 2249 patients. In addition to 
serum creatinine, diagnostic serum free light chain kappa and lambda concentrations were available in 
2136 patients. Of these, 297 (14%) patients had a serum creatinine concentration higher than 177 
µmol/L and 627 (29%) patients had an involved serum free light chain concentration higher than 1000 
mg/L. Two hundred and nine patients had both a serum creatinine concentration higher than 177 
µmol/L and an involved serum free light chain concentration higher than 1000 mg/L and were included 
in the study. Medical records in 5 patients were not accessible. The study population thus consisted of 
204 patients. Pre-myeloma kidney function was defined based on the latest serum estimated glomerular 
filtration rate (eGFR) assessment prior to myeloma diagnosis. Grades of Chronic Kidney Disease (CKD) 
were defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 
2012 Clinical Practice Guidelines; grades 1, 2, 3a, 3b, 4 and 5 were defined by eGFR values of ≥90, 60-89, 
45-59, 30-44, 15-29 and <15 ml/min/1.73 m2, respectively. Fourteen percent, 49%, 16%, 9%, 10% and 
2% of patients had pre-myeloma CKD grades 1, 2, 3a, 3b, 4 and 5, respectively. Acute kidney injury (AKI) 
stage at diagnosis was classified according to the KDIGO 2012 Clinical Practice Guideline for acute kidney 
injury; stages 1, 2 and 3 were defined as serum creatinine 1.5-1.9 times baseline or ≥25.5 µmol/L 
increase, 2.0-2.9 times baseline, and 3.0 times baseline or increase in serum creatinine to ≥353.6 µmol/L 
or initiation of renal replacement therapy, respectively. At diagnosis, 10%, 19% and 71% of patients had 
AKI stage 1, 2 and 3, respectively.  
Abbreviations: DMMR=Danish Multiple Myeloma Registry; pt.s=patients; sFLC=serum free light chain; 
CKD=chronic kidney disease; AKI=acute kidney injury 
 
Figure 2 
Renal recovery by reduction of serum involved free light chain concentration 
 
Stacked columns showing achievement of renal recovery at different time points by reduction of 
involved serum free light chain concentration. Reduction of involved free light chain to ≤10% of baseline 
is shown on the left in red, reduction to 11-50% of baseline is shown in the middle in blue and reduction 
to >50% of baseline is shown on the right in purple. In patients with dialysis-dependent renal failure at 
diagnosis, renal recovery was defined as independence from dialysis. In patients without dialysis-
dependent renal failure, renal recovery was defined as a rise in estimated glomerular filtration rate from 
<15 to ≥15, from 15-29 to ≥ 30, from 45-59 to ≥ 60 or from 60-89 to ≥ 90 ml/min/1.73 m2. Achievement 
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of renal recovery was associated with deeper reductions of involved sFLC at all time points (p=0.009 at 
the end of the first cycle of therapy, p=0.001 at three months, and p=0.002 at six months after initiation 
of therapy). 
Abbreviations: sFLC= serum involved free light chain; C1=end of first cycle of anti-myeloma therapy, 
M3=three months after initiation of anti-myeloma therapy, M6=six months after initiation of anti-
myeloma therapy, M12=twelve months after initiation of anti-myeloma therapy.  
 
Figure 3 
Overall survival by response to first line of therapy and reduction of involved serum free light chain 
concentration three months after initiation of therapy 
 
Kaplan-Meier curves showing overall survival by hematologic response to the first line of therapy (A) and 
reduction of involved serum free light chain concentration at three months after initiation of therapy 
(B). A: Patients achieving very good partial response or better (shown in blue) have superior survival 
compared to patients achieving a partial response or worse (shown in red). In order to eliminate bias, 
only patients with assessable response in their first line of therapy were included in this analysis. 
 B: Patients achieving reduction of involved free light chain concentration to ≤10% of baseline three 
months after initiation of therapy (shown in blue) have superior survival compared to patients with 
involved serum free light chain concentration >10% of baseline (shown in red). 





Abbreviations: %=percentage; IQR=interquartile range; n obs.=number of observations; 
LDH=lactatdehydrogenase; sFLC=serum free light chain; PS=Eastern Cooperative Oncology Group 
Performance Status; ISS=International Staging System; FISH=Fluorescence in situ hybridization; 
AKI=acute kidney injury 
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Baseline characteristics of the study population 
Baseline variable category present (%) Median (IQR) n obs. 
Age  72 (64; 79) 204 
Age ≤ 65 years 55 (27)   204 
Male sex 136 (67)   204 
Hemoglobin (mmol/L)  5.9 (5.3; 6.5) 203 
Hemoglobin <6.2 mmol/L 123 (61)   203 
Creatinine (µmol/L)  340 (243; 530) 204 
Ionised calcium (mmol/L)  1.26 (1.2; 1.49) 174 
Ionised Calcium ≥1.345 (mmol/L) 59 (34)   174 
β2 microglobulin (mg/L)  14 (10; 20) 176 
Albumin (g/L)  34 (29; 39) 204 
LDH (U/L)  214 (178; 260) 198 
Bone marrow clonal plasma cell infiltration (%)  50 (30; 66) 199 
Serum M-protein present 175 (86)   204 
Serum M-protein (g/L)  12 (3; 30) 160 
Involved sFLC (mg/L)  5677 (2495; 11918) 204 
Serum M-protein isotype: IgA 38 (22)   177 
Serum M-protein isotype: IgG 73 (41)   177 
Serum M-protein isotype: light chain 63 (36)   177 
Serum M-protein isotype: other 3 (2)   177 
Urine M-protein present 104 (51)   203 










Urine M-protein (g/L)  1.01 (0.45; 1.7) 62 
Urine M-protein (g/day)  1.9 (1.08; 3.99) 14 
Urin M-protein isotype: kappa 52 (54)   96 
Urin M-protein isotype: lambda 44 (46)   96 
Osteolytic lesion 122 (60)   204 
Spinal cord compression 3 (2)   204 
Amyloidosis 6 (3)   204 
Dialysis-dependent renal failure 64 (31)   204 
PS 0 57 (29)   197 
PS 1 67 (34)   197 
PS 2 45 (23)   197 
PS 3 19 (10)   197 
PS 4 9 (5)   197 
ISS I 2 (1)   176 
ISS II 9 (5)   176 
ISS III 165 (94)   176 
FISH with del17p /t(4;14) /t(14;16) 29 (21)   139 
AKI stage 1 17 (10)   171 
AKI stage 2 32 (19)   171 
AKI stage 3 122 (71)   171 
Abbreviations: %=percentage; IQR=interquartile range; n obs.=number of observations; 
LDH=lactatdehydrogenase; sFLC=serum free light chain; PS=Eastern Cooperative Oncology Group 
Performance Status; ISS=International Staging System; FISH=Fluorescence in situ hybridization; 
AKI=acute kidney injury 
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